ADCC-Enhanced Cell Line Development
ADCC-enhanced cell line development services leveraging a proprietary CHOK1-ADCC+ host cell system, designed to produce afucosylated monoclonal antibodies with enhanced immune activity.
From DNA to ADCC-Enhanced Stable Clone
Designed for ADCC Enhancement
- FUT8 knockout CHO host enables consistent afucosylation
- Improved FcγIIIa binding and effector function
Rapid Timelines
- Gene → mixed pools: 9–10 weeks
- Gene → top 6 clones: 12 weeks
- Gene → top 1 clone: 16 weeks
High Productivity
- mAb: 6-10 g/L
- Symmetric bsAb: 7-8 g/L
- Asymmetric bsAb: 4.5-7 g/L
Comprehensive Analytical Evaluation
- LC-MS
- HPLC
- Affinity to Fcγ Receptor (CD16a)
- Reporter gene assay
- PBMC-based ADCC assay
ADCC Enhanced Cell Lines, Built for the Clinic
Case Study
Enhancing Antibody Potency: Improved ADCC Activity with CHOK1-ADCC+ Cell Line System.
Resources
HAND
BOOK
Cell Line Development Solutions for Biomanufacturing
Break through to next level of productivity with our integrated solutions.
WHITE
PAPER
Optimized Cell Line Development
Strategies for Bispecific Antibody Manufacturing.
HAND
BOOK
How to Design and Evaluate Bispecific Antibodies (BsAbs)?
Develop bsAbs discovery strategies based on structure.
POSTER
CHOK1-ADCC+
High-Performance Host Cell System for ADCC Biotherapeutics.
Frequently Asked Questions